Clinical Trial Update: The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the safety and efficacy of combining regorafenib with durvalumab (MEDI4736) in chemo-refractory advanced biliary tract cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Stivarga (regorafenib)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Advanced Biliary Tract Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING